text.skipToContent text.skipToNavigation
Pharma & Biotech

Human Peripheral Blood CD14+ Monocytes, Cryopreserved, Negative Selection, 10 million

Catalog #: 4W-400
Cryopreserved ampule of Human Peripheral Blood CD14+ Monocytes, negative selection, containing ≥10 million cells
Compare
EA

Product Overview

Leukapheresed CD14+ monocytes are negatively selected from leukapheresed peripheral blood MNCs using an immunomagnetic labeling system to remove unwanted cell types leaving the monocyte untouched. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols.

Manufactured by AllCells®

Benefits

  • Test negative for mycoplasma, bacteria, yeast, and fungi
  • HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots
  • Certificate of Analysis (CoA) is provided for each cell lot purchased

Applications

  • Generate monocyte-derived M1 and M2 macrophages
  • Generate monocyte-derived DCs
  • Dendritic cell differentiation and maturation
  • Toll-like receptor and pattern recognition receptors (PRR)
  • Phagocytosis
  • Metabolism mechanisms

Content & Storage

Content

1 x Cryopreserved ampule of CD14+ Monocytes containing ≥ 10 million cells

Instructions

Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Need a Quote or Any Support?

Request a local representative to get back to you with additional information or pricing.

Immunotherapy and Hematopoietic Knowledge Center

The Immunotherapy and Hematopoietic Knowledge Center is dedicated to sharing interesting articles and resources related to immuno and hematopoietic research.

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok